104 Safety and eighteen month efficacy of pulsed field ablation in a UK cohort

Introduction Pulsed field ablation (PFA) is a novel technique used in the treatment of atrial fibrillation (AF). This is an alternative to radiofrequency/cryoablation, which are the current mainstays of ablation treatment. The Farapulse (BSCI) PFA system was first introduced into the UK in 2022 at Royal Papworth Hospital. Our objective is to describe the safety and efficacy of PFA in the first 2 years after introduction at a UK tertiary electrophysiology centre. Methods Patients undergoing PFA for AF at a single UK centre in the first eighteen months with confirmed follow-up data were included in a prospective registry. Recurrences of AF after a 90-day blanking period were defined as >30s documented AF. Patients were followed up routinely within 3 months via ECG, or by Holter monitor if they experienced symptoms. Results 123 patients (age 64 ± 10 years, Male 71%, CHA2DS2VASc score 1.8 ± 1.4, BMI 30 ± 6, Left ventricular ejection fraction Conclusion 18-month follow-up data shows that the Farapulse ablation procedure has a good safety profile (4.1% serious adverse event rate), with promising medium-term efficacy (82% freedom from AF for PAF, 62% for peAF). We await 5 year survival data which will allow for better comparison between PFA and other ablation methods. Conflict of Interest None